Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. - Wikidata - wikimedia - TriplyDB

Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.

Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.

http://www.wikidata.org/entity/Q34150125

about

SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy Wanted, dead or alive: New viral vaccines Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques.Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).Non-human primate models for AIDS vaccine research.Efficient mother-to-child transfer of antiretroviral immunity in the context of preclinical monoclonal antibody-based immunotherapy Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality.No acquisition: a new ambition for HIV vaccine development?Evidence for persistent, occult infection in neonatal macaques following perinatal transmission of simian-human immunodeficiency virus SF162P3 Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.Vectored antibody gene delivery for the prevention or treatment of HIV infection.New concepts in antibody-mediated immunity.Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006.Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques Immunological treatment of liver tumors Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked Progress and obstacles in the development of an AIDS vaccine.HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant.Biphasic CD8+ T-Cell Defense in Simian Immunodeficiency Virus Control by Acute-Phase Passive Neutralizing Antibody Immunization.Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.Animal models in virus research: their utility and limitations.Fcγ receptor pathways during active and passive immunization.Engineering broadly neutralizing antibodies for HIV prevention and therapy.

P2860

Q27014903-97A3A3B8-1D7C-4D27-BF34-785D02D14E5C Q27314576-9E1A4160-9D4C-4602-8C14-5EDC524E9CE6 Q27489979-29DE07D3-634B-443D-B90A-9D8F88BB5359 Q28068018-069877B9-E765-47FC-9623-42A2770A86D5 Q28766705-CD544F6F-52B2-4EE1-83F5-C78924A2809C Q31138949-D050F92E-40B8-42C7-802C-B83C84F3B6C7 Q33883813-AC1C8A92-8401-48FA-888C-3320A8D67BAD Q34185625-33986477-E83A-4FE7-A336-9B39F310700F Q34326222-8BED6614-4D6F-440C-8A25-B5D6153B14CC Q34527469-07BE1072-E7CC-4C2E-AAE1-BE1BBF1CCE36 Q34648499-CEC02EAD-050B-463E-A16B-AABE658BE009 Q34715769-CC192A09-7861-4731-B2F9-79265ED96B59 Q35101489-6291612C-A68C-4AD5-99DF-78AE0A0AE105 Q35352866-93825C60-0917-4935-B972-67E4C2309E9C Q35534563-FA51C981-192E-492C-AE7E-3F63E59F01AE Q35635083-6C1E5179-F99B-4100-8CD3-768C54B53D31 Q35636394-4F0E9CA0-9645-40D3-A307-6879C25A379F Q35664155-3AB026DE-3E15-434D-8E65-C25C71666BE1 Q35926507-0136E8CE-508C-421F-8DA6-77A9C70FA511 Q35947805-9DB1E1DC-FD9B-46BB-932B-5063A3DA653F Q36009232-72679AD2-EC4A-4C28-A2F6-41AD1FCBA54B Q36017488-C2128372-7896-4DDB-ACE2-5E5E2F7D4D99 Q36138144-04331CD7-0DE4-4DFC-81FB-3C1A90F50547 Q36228649-CB03C416-16FE-4858-907D-9CBAABF02CE4 Q36247783-2EBF71E7-2259-4D3F-AD92-5F01AE8DD533 Q36286484-8683A632-F952-4A65-8BBE-D8EFF83408FA Q36373254-119BE10A-9DEE-491E-872E-1742CF03845A Q36434294-4A05B383-6C32-4463-BA9E-B2307BABA97F Q36540060-23FE10B6-49DC-4FE6-8ABB-0FF943FC7EE7 Q36662462-B56065B8-111E-45AD-B829-0667950DCA1A Q37059216-709C4137-39CB-4071-B357-0BAEB2CE89E9 Q37073319-872E54D5-4747-49E9-8BB2-6252002A7E36 Q37145901-3046A823-32E1-4B22-8CDD-40500EB89A4A Q37171570-CBE634AE-A5D2-4EB9-892F-B0686F05030F Q37191899-2B4A8A3E-399F-4DB5-883E-ABB214BFFB69 Q37252831-D1D0629A-4D79-4995-BC31-3A2B54BBD2F3 Q37419234-66B5FD42-FE72-4F8D-8910-5A98947B9EB2 Q38043556-A334BD93-3478-44F8-88ED-A90766108D16 Q38615357-52BF6B07-593F-4DB6-A2D1-AEEC2F33DC30 Q38717198-D7C079C3-6E7B-4C45-B1DE-91F6A956E77B

P2860

Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.

http://www.wikidata.org/entity/Q34150125

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Passive immunotherapy in simia ...... nt of neutralizing antibodies.

@ast

Passive immunotherapy in simia ...... nt of neutralizing antibodies.

@en

Passive immunotherapy in simia ...... nt of neutralizing antibodies.

@nl

type

label

Passive immunotherapy in simia ...... nt of neutralizing antibodies.

@ast

Passive immunotherapy in simia ...... nt of neutralizing antibodies.

@en

Passive immunotherapy in simia ...... nt of neutralizing antibodies.

@nl

prefLabel

Passive immunotherapy in simia ...... nt of neutralizing antibodies.

@ast

Passive immunotherapy in simia ...... nt of neutralizing antibodies.

@en

Passive immunotherapy in simia ...... nt of neutralizing antibodies.

@nl

P1433

Q34150125-D9561A3E-55DC-483F-B116-34CCCBDD5E30

P1476

Q34150125-C2D72CB0-5E0B-42AA-90B3-E2703C6F168E

P2093

Q34150125-01EBC334-E592-4427-BA35-8CAC8BC29EDB

Q34150125-24A81F81-736E-4720-BFDC-C47091D29EFB

Q34150125-28A2CCD8-DED9-4990-A778-F371707B333A

Q34150125-549AB8EB-8CF7-4B11-91FA-5B4D2EBE3BBE

Q34150125-7E0FA82B-8C5D-4BA9-BBC8-A25B29FA30AE

Q34150125-96AA09BB-5106-474B-B1B4-CED0FFF05E6D

Q34150125-99D04415-4884-4EC6-A3FB-E9C679E85995

Q34150125-C6E62972-99C1-4B56-9EEF-A01C5DDA2534

Q34150125-CCD292DD-948E-4CAE-BEAD-567805B9141E

Q34150125-EB50FA94-ECEB-44AA-85F4-5F9514FBAC43

P2860

Q34150125-02EB1314-677D-4FB8-83B5-3A6581419BA8

Q34150125-07129962-B022-468E-88F5-281234B4D533

Q34150125-09B72542-C18E-4064-AD55-BD3C4C5ECE6D

Q34150125-164BAD87-4055-44E2-8ED2-1C1C50F243C3

Q34150125-16525FC2-30A7-4C5F-BFD9-6EBF007263AE

Q34150125-316DE988-74EC-4367-AD56-65B28535CDD2

Q34150125-360FE489-198D-4F48-811C-028B3994F504

Q34150125-384F0113-9960-4F3D-A6F6-D9852DFA1152

Q34150125-3DC1C919-303A-4488-B79C-DADC64E88078

Q34150125-42B9630F-98C0-49C2-B9B1-D50D8BAAA4D0

P304

Q34150125-6102C13A-251A-4E9F-8BD9-496209A6C1C1

P31

Q34150125-6EC73FB3-A449-4048-8F76-27B8356D383C

P356

Q34150125-EDE334C9-D73E-40AA-949D-3BFCAB0BEA9D

P407

Q34150125-64067ED3-3DEF-45D0-A968-B4A20CD819FE

P433

Q34150125-2FD4CAF0-B9E0-45A9-852B-73F54B35D9D6

P478

Q34150125-BBFF889A-AA51-42E6-8A13-26304922CF16

P50

Q34150125-2F7804E8-4370-4DE9-AE20-5971243EBD49

P577

Q34150125-93DD8F81-F675-47BA-9406-E9C334C605C8

P698

Q34150125-046B6AE0-15EF-46D5-9FD4-7C88731B5917

P921

Q34150125-1581E90D-4AEC-4DC3-9693-3F4BAA003656

Q34150125-717979D3-96A4-4C9C-9F54-A01955C85A0D

Q34150125-B957EE08-54FC-4D40-9A70-D553C9B60806

P932

Q34150125-42622EB4-CF05-416A-9211-D577CFEC544D

P356

JVI.78.11.5983-5995.2004

P1433

Journal of Virology

P1476

Passive immunotherapy in simia ...... nt of neutralizing antibodies.

@en

P2093

Andrew J Watson

http://www.w3.org/2001/XMLSchema#string

Barbra A Richardson

http://www.w3.org/2001/XMLSchema#string

Gerald Voss

http://www.w3.org/2001/XMLSchema#string

Janela McClure

http://www.w3.org/2001/XMLSchema#string

Nancy L Haigwood

http://www.w3.org/2001/XMLSchema#string

Norman L Letvin

http://www.w3.org/2001/XMLSchema#string

Philip R Johnson

http://www.w3.org/2001/XMLSchema#string

Shiu-Lok Hu

http://www.w3.org/2001/XMLSchema#string

Vanessa M Hirsch

http://www.w3.org/2001/XMLSchema#string

William F Sutton

http://www.w3.org/2001/XMLSchema#string

P2860

High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR

Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial

Antibody neutralization and escape by HIV-1

Viral dynamics in human immunodeficiency virus type 1 infection

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen

Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment

P304

5983-5995

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.78.11.5983-5995.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P50

David C Montefiori

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15140996

http://www.w3.org/2001/XMLSchema#string

P921

Simian immunodeficiency virus

P932

415787

http://www.w3.org/2001/XMLSchema#string